Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas

European Journal of Gynaecological Oncology

Volumn 29, Issue 3, 2008, Pages 246-251

  Sung, P L ^a,b   Chen, Y J ^a,b   Liu, R S ^a,b   Shieh, H J ^a,b   Wang, P H ^a,b   Yen, M S ^a,b   Wen, K C ^a,b   Shen, S H ^a,b   Lai, C R ^a,b   Yuan, C C ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

FDG PET; Post treatment surveillance; Recurrent uterine sarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAPHRAGM; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; PARAAORTIC LYMPH NODE; PELVIC DISEASE; PHYSICAL EXAMINATION; RECURRENT CANCER; SENSITIVITY ANALYSIS; SPINE METASTASIS; SPLEEN CANCER; STATISTICAL SIGNIFICANCE; UTERUS SARCOMA; WHOLE BODY PET;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PELVIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECURRENCE; SARCOMA; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; UTERINE NEOPLASMS; WHOLE BODY IMAGING;

EID: 44349181951     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Anne T. O'Meara: "Uterine sarcomas: have we made any progress". Curr .Opin. in Obstet. Gynecol., 2004, 16, 1.
2. th edition, St. Louis, MO, Mosby, 2002, 173.
3. Michael C., Lois M.R., Snuha J., Yhomas W.B., Patricia J.E.: "Malignant mixed mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors and treatment outcome". Int. J. Radiat. Oncol. Biol. Phys., 2004, 58, 786.
4. Goff B.A., Rice L.W., Fleischhacker D., Muntz H.G., Falkenberry S.S., Nikrui N. et al.: "Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence". Gynecol. Oncol., 1993, 50, 105.
5. Gadducci A., Landoni F, Sartori E., Zola P., Maggino T., Lissoni A. et al.: "Uterine leiomyosarcoma: analysis of treatment failures and survival". Gynecol. Oncol., 1996, 62, 25.
6. Mayerhofer K., Obermair A., Windbichler G., Petru E., Kaider A., Hefler L. et al.: "Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases". Gynecol. Oncol., 1999, 74, 196.
7. Omura G.A., Blessing J.A., Major F., Lifshitz S., Ehrlich C.E., Mangan C. et al.: "A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study". J. Clin. Oncol., 1985, 3, 1240.
8. Hornback N.B., Omura G., Major F.J.: "Observations on the use of adjuvant radiation therapy in patients with Stage I and II uterine sarcoma". Int. J. Radiat. Oncol. Biol. Phys., 1986, 12, 2127.
9. Nordal R.R., Thoresen S.O.: "Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality". Eu.r J. Cancer, 1997, 33, 907.
10. Satoru S., Kohki Y., Shinichi I. et al.: "Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan". Oncology, 2004, 67, 33.
11. Kinkel K., Ariche M., Tardivon A.A., Spatz A., Castaigne D., Lgomme C. et al.: "Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carinoma: value of dynamic contrast-enhanced subtraction MR imaging". Radiology, 1997, 204, 55.
12. Siegelman E.S., Outwater E.K.: "Tissue characterization in thefe-male pelvis by means of MR imaging". Radiology, 1999, 212, 5.
13. Ebner F., Kressel H.Y., Mintz M.C., Carlson J.A., Cohen E.K., Schiebler M. et al.: "Tumor recurrence versus fibrosis in the female pelvis: differentiation with MR imaging at 1.5 T". Radiology, 1988, 166, 333.
14. Connor J.P., Andrews J.I., Anderson B., Buller R.E.: "Computed tomography in endometrial carcinoma". Obstet. Gynecol., 2000, 95, 69.
15. Feong Y.Y., Kang H.K., Chyng T.W., Fin F., Park F.G.: "Uterine cervical carcinoma after therapy: CT and MR imaging findings". Radiographics, 2003, 23, 969.
16. Moskovic E., MacSweeney E., Law M., Price A.: "Survival patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients". Br. J. Radiol., 1993, 66, 791, 1009.
17. Patsner B., Mann W.J.: "Use of serum CA-125 in monitoring patients with uterine sarcoma. A preliminary report". Cancer, 1988, 62, 1355.
18. Umesaki N., Tanaka T., Miyama M., Ogita S., Kawabe J., Okamura T. et al.: "Positron emission tomography using 2-[18F]-fluoro-2 -deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma: A case report". J. Nucl. Med., 2001, 25, 203.
19. Umesaki N., Tanaka T., Miyama M., Kawamura N., Ogita S., Kawabe J. et al.: "Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging". Gynecol. Oncol., 2001, 80, 372.
20. Jadvar H., Fischman A.J.: "Evalation of rare tumors with [F-18]fluorodeoxyglucose positron emission tomography". Clin. Post. Imag., 1999, 2, 153.
21. Murakami M., Tsukada H., Shida M., Watanabe M., Maeda H., Koido S. et al.: "Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcoma". Int. J. Gynecol. Cancer., 2006, 16, 854.
22. Leitao M.M., Brennan M.F., Hensley M., Sonoda Y, Hummer A., Bhaskaran D. et al.: "Surgical resection of pulmonary and extrapulonary recurrences of uterine leiomyosarcoma". Gynecol. Oncol., 2002, 87, 287.
23. Dinh T.A., Oliva E.A., Fuller Jr. A.F., Lee H., Goodman A.: "The treatment of uterine leiomyosarcoma .Result from a 10-year experience (1990-1999) at the Massachusetts General Hospital". Gynecol. Oncol., 2004, 92, 648.
24. Bomanji J.B., Costa D.C., Ell P.J.: "Clinical role of positron emission tomography in oncology". Lancet Oncol., 2001, 2, 157.
25. Zimny M., Siggelkow W., Schroder W., Nowak B., Biemann S., Rath W. et al.: "2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer". Gynecol. Oncol., 2001, 83, 310.
26. Jimenez-Bonilla J., Maldonado A., Morales S., Salud A., Xomeno M., Roman J. et al.: "Clinical impact of 18 F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels". Clin. Positron Imaging., 2000, 3, 231.
27. Park D.H., Kim K.H., Park S.Y., Lee B.H., Choi C.W., Chin S.Y.: "Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography". Korean. J. Radiol., 2000, 1, 151.
28. Kerr I.G., Manji M.F., Powe J., Bakheet S., Al Suhaibani H., Subhi J.: "Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix: A retrospective review". Gynecol. Oncol., 2001, 81, 477.
29. Pandit-Taskar N.: "Oncologic imaging in gynecologic malignancies". J. Nucl. Med., 2005, 46, 1842.
30. Wahl R.L.: "Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT". J. Nucl. Med., 2004, 45, 82S.
31. Belhocine T.: "An appraisal of 18F-FDG PET image in post-therapy surveillance of uterine cancers: clinical evidence and a research proposal". Int. J. Gynecol. Cancer, 2003, 13, 228.
32. Nakamoto Y, Eisbruch S., Achtyes E.D., Sugawara Y., Reynolds K.R., Johnston C.M. et al.: "Prognostic value of positron emission tomography using F-18-flurodexoyglucose in patients with cervical cancer undergoing radiotherapy". Gynecol. Oncol., 2002, 84, 289.